2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A, Coffey C, Lasch S, Aarsland D, Burn D, Chahine LM, Espay AJ, Foster ED, Hawkins KA, Litvan I, Richard I, Weintraub D, Initiative T. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLOS ONE 2017, 12: e0175674. PMID: 28520803, PMCID: PMC5435130, DOI: 10.1371/journal.pone.0175674.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCognitive DysfunctionDiffusion Tensor ImagingDopamine Plasma Membrane Transport ProteinsFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedParkinson DiseasePolymorphism, Single Nucleotidetau ProteinsTomography, Emission-Computed, Single-PhotonConceptsParkinson's diseaseCognitive impairmentDe novo Parkinson's diseaseDopamine transporter single-photon emissionLongitudinal mixed-effects modelsNovo Parkinson's diseaseYears of diseaseIdiopathic Parkinson's diseaseMovement Disorders CenterSingle nucleotide polymorphismsStructural magnetic resonance imagingClinical trial designLongitudinal structural MRIMagnetic resonance imagingSingle photon emissionDevelopment of treatmentsDiffusion tensor imagingBiomarker predictorsPlaque pathologyAmyloid pathologyDopamine deficiencyDopaminergic deficitUnivariate analysisBiomarker changesDisorders Center
2012
A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC).
Tolaney S, Duda D, Boucher Y, Goel S, Martin J, Ancukiewicz M, Potler H, Incio J, Ligibel J, Isakoff S, Fukumura D, Winer E, Krop I, Jain R. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 1026-1026. DOI: 10.1200/jco.2012.30.15_suppl.1026.Peer-Reviewed Original ResearchTN breast cancerBreast cancerInterstitial fluid pressureMiller-PayneTN tumorsHER2-negative operable breast cancerMean interstitial fluid pressureHormone receptorsMP responseAddition of BevAxillary LN involvementDose-dense doxorubicinTriple-negative cohortOperable breast cancerPhase II studyPredictors of responseMean vascular densityPreoperative bevacizumabLN involvementII studyOverall cohortPathologic responseBiomarker predictorsNegative cohortPharmacodynamic effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply